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Thiram-tetramethylthiuram disulphide – a chelator of heavy metals, inhibited DNA synthesis and induced apoptosis in
cultured bovine capillary endothelial cells. Bovine capillary endothelial cells were 10–60-fold more sensitive to thiram than
other cell types. These effects were prevented by addition of antioxidants, indicating involvement of reactive oxygen species.
Exogenously added Cu
2+ impeded speciﬁcally and almost completely the inhibitory effect of thiram for bovine capillary
endothelial cells. Moreover, thiram had markedly inhibited human recombinant Cu/Zn superoxide dismutase enzymatic activity
(85%) in vitro. Moreover, PC12-SOD cells with elevated Cu/Zn superoxide dismutase were less sensitive to thiram treatment
than control cells. These data indicate that the effects of thiram are mediated by inhibition of Cu/Zn superoxide dismutase
activity. Oral administration of thiram (13–30 mg mouse
71), inhibited angiogenesis in CD1 nude mice. Tumour development
is known to largely depend on angiogenesis. We found that oral administration of thiram (30 mg) to mice caused signiﬁcant
inhibition of C6 glioma tumour development (60%) and marked reduction (by 3–5-fold) in metastatic growth of Lewis lung
carcinoma. The data establish thiram as a potential inhibitor of angiogenesis and raise the possibility for its use as therapy in
pathologies in which neovascularisation is involved, including neoplasia.
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Angiogenesis, the growth of new capillary blood vessels by
sprouting from established vessels, is a tightly controlled process
(Folkman and Klagsburn, 1987; Folkman, 1990, 1995). The
hypoxic induction of angiogenesis is a hallmark of pathological
processes such as wound healing and solid tumour formation.
This hypoxic induction of new blood vessel formation is
strongly correlated also with the disrupted circulation, the rapid
proliferation and growth characteristic of these states. Angiogen-
esis involves intense endothelial cell cytokine-dependent
proliferation and hypoxia/re-oxygenation. Cultured endothelial
cells produce reactive oxygen species (ROS) spontaneously
(Sundqvist, 1991; Terada et al, 1991) and this is augmented
by hypoxia/reoxygenation (Ratych et al, 1987; Inauen et al,
1990; Lum et al, 1992; Zweier et al, 1988, 1994a,b; Terada,
1996) as well as by cytokines (Matsubara and Ziff, 1986). In
vivo, oxygen radicals are also produced as by-products of
normal oxidative metabolism (Malmstrom, 1982). Hence, prolif-
erating cells with a higher metabolism produce more oxygen
radicals. ROS have been implicated in the mechanism of
damage following reperfusion of ischaemia (McCord, 1985),
and vascular endothelial cells are the most vulnerable targets
for free radicals produced at the time of organ reperfusion after
cold preservation (Connor et al, 1992). Angiogenesis is a
continuous process of re-oxygenation. The fact that ROS are
produced by endothelial cells, especially under conditions of
re-oxygenation and the very high sensitivity of endothelial cells
to ROS poses a physiological need to scavenge these toxic
oxygen radicals, which otherwise will lead to damage and apop-
tosis of the vasculature.
Cu/Zn superoxide dismutase (SOD-1) is a key enzyme in
the dismutation of the potentially toxic superoxide radicals
into hydrogen peroxide and dioxygen (Fridovich, 1978). We
have recently shown that transgenic mice over-expressing
human SOD-1 have a higher angiogenic potential than control
non-transgenic mice (Marikovsky et al, 2002). Since angiogen-
esis is characterised by proliferating endothelial cells and re-
oxygenation, we speculated that inhibition of SOD-1 will
diminish the ability of endothelial cells to confront the
increased level of ROS during angiogenesis, thus, resulting
in inhibition of angiogenesis, of tumour development and
metastasis. This assumption is consistent with recent ﬁndings
demonstrating that the anti-angiogenic compound 2-methoxy-
oestradiol (Fotsis et al, 1994) is a SOD-1 inhibitor (Huang
et al, 2000).
Thiram-tetramethylthiuram disulphide (TR) is a fungicide and
a heavy metal chelator. Here we demonstrate that TR inhibits
SOD-1 activity in vitro, induces apoptosis in endothelial cells
in vitro and inhibits angiogenesis in vivo. Tumour growth is
dependent upon the formation of new blood vessels in the
tumour and its surroundings (Folkman, 1990, 1995). To deter-
mine if systemic administration of TR could inhibit an
angiogenesis-dependent tumorigenesis, two models were used.
TR inhibited by 60% C6 glioma tumour development and
reduced by 3–5-fold the metastatic load of Lewis lung carcino-
ma in mouse lungs. These data suggest that TR, an inhibitor of
SOD-1, may affect angiogenesis and raise the possibility for the
use of TR as therapy in pathologies in which neovascularisation
is involved, including neoplasia.
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Materials
Thiram (Sigma, St Louis, MO, USA), N-Acetyl-L-cysteine (NAC),
4,5-dihydroxy-1,3 benzene-disulphonic acid (Tiron), Glutathione
(reduced) were all purchased from Sigma St Louis, MO, USA).
Recombinant basic ﬁbroblast growth factor (b-FGF) was kindly
provided by Prof G Neufeld. Mouse epidermal growth factor
(EGF) was purchased from Collaborative Biomedical Products
(Bedford, MA, USA). Recombinant heparin-binding EGF (HB-
EGF) was kindly provided by Dr Judith A Abraham (Scios Nova
Inc., Mountain View, CA, USA).
Cell lines
C6 rat glioma cells were routinely cultured in DMEM (Dulbecco’s
Modiﬁed Eagle’s Medium) supplemented with 5% foetal calf serum
(FCS, Biological Industries, Israel), penicillin (100 U ml
71), strep-
tomycin (100 mg ml
71) (Biological Industries, Israel) and 2 mM
glutamine (Biolab Ltd., Israel) (GPS) and 125 mgm l
71 fungizone
(Biolab Ltd., Israel). The metastatic clone D122 was kindly
provided by Prof L Eisenbach (Weizmann Institute, Rehovot,
Israel) and was used by us for tissue culture and for in vivo experi-
ments. D122 cell cultures were maintained in DMEM
supplemented with 10% heat-inactivated foetal calf serum (FCS,
Biological Industries, Israel), penicillin (100 U ml
71), streptomycin
(100 mg ml
71) (Biological Industries, Israel), 2 mM glutamine
(Biolab Ltd. Israel), sodium pyruvate (1 mM) and nonessential
amino acids (Biological Industries, Israel). Brain bovine capillary
endothelial cells (BCE), bovine aortic endothelial cells (BAE) and
bovine vascular smooth muscle cells (BSMC) were kindly provided
by Prof I Vlodavsky. BCE and BAE were cultured at 378C in low
glucose DMEM (1 g l
71) supplemented with 10% calf serum
(HyClone, Logan, UT, USA), basic ﬁbroblast growth factor (bFGF)
(1 ng ml
71) and GPS. BSMC and 3T3 ﬁbroblasts were cultured in
normal glucose DMEM (4.5 g l
71) supplemented with 10% foetal
calf serum (HyClone, Logan, UT, USA) and GPS. The BALB/MK
epidermal keratinocyte cell line (kindly provided by Dr S Aaronson,
National Cancer Institute, Bethesda, MD, USA), were cultured as
described (Rubin et al, 1989; Marikovsky et al, 1993, 1995, 1996).
Cu/Zn superoxide dismutase (SOD-1)-transfected PC12 cells were
kindly donated by Prof Y Groner (Weizmann Institute, Rehovot).
PC12 cells over-expressing SOD-1 (P) were transfected with a plas-
mid containing full length of human recombinant SOD-1. Parental
PC12 cells (N) were transfected with a plasmid containing only the
NEO resistant gene (control) as previously described (Elroy Stein
and Groner, 1988). PC12 cells were grown in DMEM containing
10% FCS (Biological Industries, Israel) and 10% horse serum
(Gibco, Grand Island, NY, USA) in presence of G418 Geneticin
Sulphate (NEO) 400 mgm l
71 (Gibco BRL).
Measurement of DNA synthesis
C6 rat glioma cells were plated in 96-well plates (Nunc, Denmark)
(5000 cells per well) in DMEM with 5% FCS. After 6 h the cells
were rinsed and incubated for 48 h in serum free medium. FCS
(5%) was then added to the cells for 24 h. TR was added for
24 h at various concentrations. [
3H]-methyl-thymidine (5 mCi
ml
71) (ROTEM Ind. Ltd. Israel) was added to the cells for the last
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Figure 1 TR inhibits DNA synthesis in various cell types. DNA synthesis
was measured by the incorporation of [
3H]-thymidine into the cells, as de-
scribed in Materials and Methods. TR at various concentrations was incu-
bated with BCE, BSMC, BALB/MK, C6 rat glioma cells and with D122
cells as described in Materials and Methods. TR inhibited in a dose-depen-
dent manner DNA synthesis in various cell types. Experiments were done
in triplicates and inhibition was calculated as percentage of DNA synthesis
of non-treated control.
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(6000 cells per well) in 500 ml growth medium. After 24 h TR
was added for 24 h at various concentrations. [
3H]-methyl-thymi-
dine was added for the last 6 h. DNA synthesis assay in BALB/MK
keratinocytes was performed as previously described (Rubin et al,
1989; Marikovsky et al, 1993, 1995, 1996). PC12 cells were plated
in 96-well plates (5000 cells per well) in 200 ml growth medium.
After 24 h TR was added for 24 h at various concentrations.
[
3H]-methyl-thymidine was added for the last 6 h. All DNA synth-
esis assays were performed in triplicates.
TR was prepared in 10 mM stock solutions in DMSO. Control
samples were incubated with the appropriate concentration of
DMSO. Inhibition was calculated as percentage of DNA synthesis
of control. Antioxidants were co-incubated with TR and recovery
of DNA synthesis was calculated as percentage of DNA synthesis
of control.
TUNEL assay for apoptosis
Cells were cultured on microscope slides for 48 h in presence of
growth media as described (Abramovitch et al, 1998b, 1999; Mari-
kovsky et al, 1993, 1995, 1996), until reaching 30–40% conﬂuence.
TR was then added to the cells for 6 h or for 20 h in the case of
BALB/MK keratinocytes. Cells were ﬁxed with 4% paraformalde-
hyde. Apoptosis was analysed by the in situ TUNEL staining that
was carried out as before (Wride et al, 1994). The slides were then
stained with haematoxylin. Experiments were repeated twice with
triplicates.
Inhibition of SOD activity
SOD-1 activity was determined as described (Elroy Stein et al,
1986). Various concentrations of TR were incubated in the
presence of human recombinant SOD-1 (20 ng ml
71). Experi-
ments were repeated twice.
Subcutaneous angiogenesis in nude mice
Agarose beads containing b-FGF or HB-EGF (10 mg bead
71).
Beads were implanted subcutaneously 1 cm away from the incision
site as described (Abramovitch et al, 1998a,b; 1995). Experiments
were carried out for 4 days in CD1 nude male mice. Each day
an aqueous solution with or without TR (13–30 mg mouse
71)
was introduced per os (p.o.) to the mice using a feeding needle.
Treatment was for 3 days starting from the day of bead implanta-
tion until 1 day before termination. Experimental group included
four animals and experiments were repeated three times. Quantita-
tive analysis was done by use of NIH Image 1.61 software.
Growth of C6 glioma tumours
C6 rat glioma cells (10
6) were injected subcutaneously into the
back of the neck of CD1 nude male mice. Three days following
tumour cells injection, aqueous solutions with or without TR
(25–120 mg mouse
71) were introduced p.o. to the mice using a
feeding needle. Mice were treated three times per week. Mice were
sacriﬁced 30 days following C6 cells injection by injecting
20 mg mouse
71 Xylazine (i.p.) and tumours were removed,
weighed, ﬁxed in buffered formalin and histological sections were
prepared and stained with Haematoxylin-Eosin and light green.
Blood vessels were stained with the endothelial-speciﬁc Bandeirea
simplicifolia agglutinin-I (GSL) (Sigma Inc., St Louis, MO, USA)
as described (Alroy et al, 1987). Blood vessels count was the aver-
age of ﬁve different 6400 fields. Each experimental group included
eight animals, and experiments were repeated twice.
Metastasis of Lewis lung carcinoma tumours to the lungs
The Lewis lung carcinoma (3LL), which originated spontaneously
in a C57/BL/6J(H-2
b) mouse, is a malignant tumour that produces
spontaneous lung metastases. The metastatic clone D122, was
kindly provided by Prof L Eisenbach, and was used by us for tissue
culture and for in vivo experiments.
D122 cells (5610
5) were injected i.v. to the tail of C57/BL male
mice (8–10 weeks old) and TR (13–40 mg mouse
71) or water
were administered p.o. three times per week and was started 3 days
following tumour cell injection. Mice were sacriﬁced 24 days
following injection of D122 cells by injecting 20 mg mouse
71 Xyla-
zine (i.p.) and lungs were weighed. Each experimental group
included eight animals, and experiments were repeated twice.
The animal ethics in all animal experiments meet the standards
required by the UKCCCR Guidelines for the welfare of animals in
experimental neoplasia (second edition), as stated in the ‘Instruc-
tions to Authors’ forms.
RESULTS
Inhibition of capillary endothelial cell proliferation in vitro
by TR
We have examined the effect of TR on the growth of capillary
endothelial cells in vitro. DNA synthesis in BCE cells was measured
in the presence of increasing concentrations of TR incubated for
24 h with the cells. TR was able to inhibit DNA synthesis in
BCE cells in a dose dependent manner (Figure 1). Complete inhi-
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Table 1 Copper impedes the inhibitory effect of TR on BCE cells
a
Cu
2+ (2 mM) DNA synthesis (% control)
Control 7 100+5
Control + 104+1
TR (0.2 mM) 7 18+4
TR (0.2 mM)+ 9 5 +1
aBCE were incubated with TR (0.2 mM) with or without preincubation in the
presence of Cu
2+ (2 mM). DNA synthesis was measured as described in Materials
and Methods and inhibition was calculated as percentage of DNA synthesis of
non-treated control. Experiments were repeated twice. DNA synthesis in control
cells was about 50 000 c.p.m.
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Figure 2 TR inhibits SOD-1 activity in vitro. Various concentrations of TR
were incubated with 20 ng ml
71 of human recombinant SOD-1. SOD-1
activity was measured as described in Materials and Methods and calculated
as per cent from the activity of control non-treated 20 ng ml
71 SOD-1. TR
had markedly inhibited human recombinant SOD-1 enzymatic activity
(85%). Experiments were repeated twice.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 779–787bition of DNA synthesis was shown at 50 nM TR (Figure 1). BAE
cells demonstrated similar results to those of BCE (not shown).
Both endothelial cell types were 10–60-fold more sensitive to the
inhibitory effect of TR on DNA synthesis than other cell types such
as BALB/MK keratinocytes, C6 rat glioma cells, D122 Lewis lung
carcinoma or BSMC. The inhibitory effect of TR was irreversible
(not shown).
Inhibition of capillary endothelial cell proliferation in vitro
by TR is reversed by copper
TR is a chelator of heavy metals. We have examined the possibility
that its inhibitory effect for endothelial cells is via this characteris-
tics. Exogenously added Cu
2+ abolished the inhibitory effect of TR
for BCE by preincubating the reagent with 2 mM Cu
2+ (Table 1),
but not with other metals such as Zn
2+,N i
2+,M n
2+ or Fe
2+ (not
shown). Copper alone, at 2 mM, had no effect on BCE.
TR inhibits superoxide dismutase activity in vitro
Cu/Zn superoxide dismutase (SOD-1) is a protective enzyme
responsible for maintaining lower levels of superoxide radicals
within the cell (Fridovich, 1978). Copper is essential for the enzy-
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Figure 4 Over-expression of SOD-1 in PC12 cells renders them more
resistant to the inhibitory effect of TR. Parental non-transfected (open cir-
cle) and SOD-1-transfected (solid circle) PC12 cells were incubated in the
presence of various concentrations of TR, and DNA synthesis was mea-
sured as described in Materials and Methods. The effect of TR was calcu-
lated as per cent of DNA synthesis compared with that in control cells not
treated with TR. PC12 cells transfected with human SOD-1 were more re-
sistant to the inhibitory effect of TR than parental non-transfected PC12
cells. DNA synthesis in PC12 non-treated cells was about 30000 c.p.m.
Control TR
BCE
BSMC
MK
1 mM
1 mM
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1 mM
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glioma
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Figure 5 TR induces apoptosis in endothelial cells. BCE, BSMC, BALB/
MK keratinocytes, C6 glioma cells and 3T3 ﬁbroblasts following incubation
with the indicated concentrations of TR for 6 h or for 20 h with BALB/MK,
were analysed by the TUNEL method as described in Materials and Meth-
ods. Only the nuclei of treated BCE were labelled using the TUNEL staining
method. The nuclei of treated BSMC, BALB/MK C6 glioma cells and 3T3
ﬁbroblasts were not labelled. Experiments were repeated twice with tripli-
cates.
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Figure 3 Antioxidants prevent the inhibitory effect of TR on endothelial
cells. N-acetylcysteine: NAC (3 mM), glutathione: Glut. (3 mM) and Tiron
(5 mM) were co-incubated with 0.1 mM of TR for 24 h and DNA synthesis
was measured as described in Materials and Methods. The effect of antiox-
idants was calculated as per cent of DNA synthesis compared with that in
control cells treated with antioxidants alone. Inhibition of DNA synthesis in
BCE by TR was fully restored by co-incubation with antioxidants. DNA
synthesis in control cells was about 50000 c.p.m.
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reversed the inhibitory effect of TR on endothelial cells, we thought
that TR effect might be via SOD-1. At concentrations similar to
those used in the biological assays, TR had markedly (85%) and
in a dose dependent manner inhibited pure recombinant human
SOD-1 enzymatic activity (Figure 2). It is possible thus, that TR
inhibits endothelial cell growth by inhibiting SOD-1 through the
chelation of its copper moiety.
Antioxidants prevent the inhibitory effect of TR for
endothelial cells
Inhibition of SOD-1 activity may alter the delicate balance of ROS
within the cell. We therefore examined the effect of antioxidants on
TR inhibition. Addition of the antioxidants: N-acetyl cysteine
(NAC), reduced glutathione and Tiron (a selective scavenger of
O2
-) signiﬁcantly reversed the inhibitory effect of TR (Figure 3).
This indicates that the inhibitory effect of TR on endothelial cells
involves increase in production of ROS. Interestingly, exogenously
added human recombinant SOD-1 did not affect the inhibition
induced by TR indicating that TR effect is intra-cellular and that
the ROS function internally.
PC12 cells over-expressing SOD-1 are more resistant to
inhibition by TR
SOD-1 – an important ROS scavenger – is essential for the survi-
val of proliferating cells. The data presented in Figures 2 and 3
demonstrate that TR: (1) inhibits the enzymatic activity of SOD-
1 and (2) increases ROS level in BCE cells as a result of SOD-1
inhibition to dismutate superoxide into H2O2, indicate that TR
inhibits SOD-1 in BCE cells. To further support the notion that
over-expression of SOD-1 is a general mechanism to confer resis-
tance to TR we reasoned that any cell type expressing higher
levels of SOD-1 will better tolerate the inhibitory effect of TR.
Stably transfected PC12 cells that over-express SOD-1 (two-fold)
(Elroy Stein and Groner, 1988), were treated with TR and DNA
synthesis was monitored in comparison to parental cells. As shown
in Figure 4 proliferating PC12 cells, which elevated SOD-1, were
less sensitive to the inhibitory effect of TR than the corresponding
parental cells. This result further supports the notion that the
effects of TR are mediated via inhibition of SOD-1.
TR induces apoptosis in cultured endothelial cells
To further characterize the mechanism by which TR inhibits BCE
cell growth, treated BCE cells were assayed for induction of apop-
tosis by the TUNEL method. BCE cells (40–50% conﬂuence) that
were incubated for 6 h with 1 mM of TR underwent apoptosis as
evident by the positive TUNEL signals (Figure 5). In contrast,
TR did not induce apoptosis in several other cell types: BSMC
(1 mM), 3T3 ﬁbroblasts (1 mM), C6 rat glioma cells (5 mM) and
BALB/MK keratinocytes (5 mM) (Figure 5). Capillary endothelial
cells are, thus, distinct in their apparent sensitivity to the TR-
induced apoptosis. Typically for cells undergoing apoptosis,
endothelial cells treated with TR, quickly became rounded and later
on detached from the plate. In contrast, the other cell types exam-
ined did not change their shape when treated with TR.
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Figure 6 TR inhibits neovascularisation in CD1 mice. Agarose beads containing bFGF (10 mg bead
71) were implanted subcutaneously as described in
Materials and Methods. (A) The angiogenic potential of bFGF in vivo is demonstrated 4 days after implantation in skin specimens. TR (13–30 mg mouse
71
day
71) was introduced p.o. every day starting with bead implantation. TR inhibited almost completely in a dose dependent manner neovascularisation inside
and around the bead. Bar is 1 mm. (B) Quantitative analysis of blood vessel density around and inside the beads. Quantitative analysis was done by use of
NIH Image 1.61 software. TR at 13–30 mg mouse
71 day
71 inhibited angiogenesis by 80–95% respectively (n=4).
Table 2 TR inhibits C6 glioma tumour growth
a
Tumour weight
(n) (gr)
b (% inhibition) P value
c
Control 8 1.37+0.21 0
TR (25 mg) 8 0.57+0.12 58 0.004
TR (120 mg) 8 0.79+0.21 42 0.04
aCD1 nude mice were fed p.o. three times a week with TR (25–
120 mg mouse
71 day
71), starting on the third day following tumour injection.
Experiments were repeated twice.
bTumours were weighed 30 days following admin-
istration of C6 cells. Indicated values are mean of (n) animals+s.e.m.
cSigniﬁcance of
difference between control and treated animals as determined by a Student’s t-test.
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(0.3–3 mM) did not change their shape to the rounded form or
became detached, neither was their DNA synthesis affected (not
shown). This may suggest that TR affects endothelial cells in a cell
cycle-dependent manner. Supporting results were obtained by
FACS analysis (not shown). DNA content analysis of BCE cells
incubated with 0.3–5 mM of TR demonstrated appearance of a
signiﬁcant sub-diploid apoptotic population of cells. Most of the
cells that were not in the apoptotic population, were found in
the G0/G1 phase (not shown).
Inhibition of in vivo neovascularisation by TR
Following the observation that TR induces apoptosis in endothelial
cells, we examined the effect of TR on angiogenesis. Basic FGF was
implanted subcutaneously into CD1 nude mice. After 4 days new
blood vessels clearly developed around and inside the beads
containing the angiogenic factor (Figure 6A). Blood vessel forma-
tion around the FGF beads was very intense and seems very
dense since it reﬂects the various layers of vessels in the bead.
The saline-containing control beads appeared on the other hand,
clear and without any new blood vessels being formed around or
within the beads (Figure 6A). Signiﬁcantly, when mice were fed
daily p.o. during 3 days with 30 mg mouse
71 day
71 of TR, angio-
genesis around and inside the bFGF-containing beads was
markedly reduced (Figure 6A). Quantitative analysis of the appar-
ent blood vessel density around and inside the beads demonstrates
a dose dependent inhibition of angiogenesis (Figure 6B). TR at
13–30 mg inhibited angiogenesis by 80–95% respectively. Similar
results were obtained when HB-EGF which induces expression of
vascular endothelial growth factor (VEGF) (Abramovitch et al,
1998b) was used instead of bFGF (not shown). The data show that
TR inhibits induced angiogenesis and that the inhibition is not
restricted to one speciﬁc inducer. Visual examination of various
tissues (kidney, liver, stomach, lungs and spleen) of TR treated
CD1 mice as well as histological sections prepared from these
tissues revealed no pathological ﬁndings in the tissues or in their
already established blood vessels.
TR inhibits C6 glioma tumour growth in vivo
TR inhibited neovascularisation in vivo and C6 glioma cell growth
in culture. Since active angiogenesis is essential for the progressive
growth of solid tumours beyond a diameter of a few millimetres
(Folkman, 1990), we examined whether systemic treatment with
TR will slow tumour development. TR at concentrations that
caused inhibition of angiogenesis in vivo, signiﬁcantly retarded
C6 glioma tumour growth in CD1 nude mice. The lower concen-
tration (25 mg mouse
71) was more effective than the higher dose
(120 mg mouse
71) (Table 2). This ﬁnding is consistent with the
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Figure 7 Histological sections of C6 tumours stained with Haematoxy-
lin-Eosin and light green. C6 tumours from TR-treated animals are different
from C6 tumours from control non-treated animals. Cells in tumours from
control non-treated animals have a more pleomorphic appearance, with a
bizarre form. Cell size and shape in tumours from TR-treated (TR 25 mg)
or (TR 120 mg) animals are more uniform and are more differentiated (nu-
clei stain and shape). Magniﬁcation (6120).
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Figure 8 TR reduces blood vessel number in C6 tumours. Histological
sections of C6 glioma tumours were stained for Haematoxylin-Eosin and
light green followed by staining with the endothelial-speciﬁc GSL lectin
(dark blue staining) as described in Materials and Methods. The number
of blood vessels per ﬁeld in C6 tumours derived from mice treated with
TR (25 mg) was reduced by 33% compared with non-treated control
(10.8+0.41 s.e. and 16.1+0.47 s.e., accordingly (P50.0003).
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Figure 9 TR inhibits Lewis lung metastatic growth in the lungs. D122 tu-
mour cells were injected into C57/BL mice and 3 days later TR (13–
40 mg mouse
71) was introduced p.o. three times a week. Twenty-four
days following tumour injection, the lungs were weighed. Metastatic growth
in the lungs of TR-treated animals, compared with that in water-fed control
was signiﬁcantly smaller (P=0.019–0.05) (n=6). At 13–40 mg mouse
71
TR decreased metastatic growth in the lungs 5–3-fold accordingly. Experi-
ments were repeated twice. The weight of lungs derived from normal mice
was subtracted from that of the metastasised lungs. P by student’s t-test.
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cell growth (not shown). This may be due to polymerisation of TR
at higher concentration. Since TR inhibits both angiogenesis in vivo
and C6 in culture, it is possible that tumour growth inhibition may
have resulted from inhibition of neovascularisation combined with
inhibition of tumour cell growth. Histological sections prepared
from C6 tumours and stained for Hematoxylin-Eosin and light
green demonstrated a clear difference in the appearance of C6 cells
in tumours from TR-treated animals vs C6 cells in tumours from
control non-treated animals (Figure 7). Cells in tumours from
control non-treated animals have a more pleomorphic appearance,
with a bizarre form. The tumour is made of a mixture of small and
large cells, most of them undifferentiated with various orientations
and polarisation. Cell size and shape in tumours from TR-treated
animals are more uniform and are more differentiated (nuclei stain
and shape).
Visual examination of various tissues (kidney, liver, stomach,
lungs and spleen) of TR treated CD1 mice as well as histological
sections prepared from these tissues revealed no pathological ﬁnd-
ings in the tissues or in their already established blood vessels.
However, histological sections of C6 glioma tumours stained with
the endothelial-speciﬁc GSL lectin have demonstrated that the
number of blood vessels per ﬁeld (6400) in C6 tumours derived
from mice treated with TR (25 mg) was reduced by 33% compared
with non-treated control (10.8+0.41 s.e. and 16.1+0.47 s.e.,
accordingly (P50.0003)) (Figure 8).
TR inhibits Lewis lung metastasis
We next examined the effect of TR on metastatic growth using the
Lewis lung carcinoma model in C57/BL mice, using concentrations
that were shown to be inhibitory for angiogenesis in vivo.
We have used the i.v. model. Three days following D122
tumour cell injection, TR was introduced p.o. three times per
week, at concentrations of 13–40 mg mouse
71 and the growth
of metastatic foci in the lungs was inhibited by 83–68%
accordingly (Figure 9). Since TR inhibits both angiogenesis in
vivo and D122 cells in culture, it is possible that inhibition of
metastatic foci growth may have resulted from inhibition of
neovascularisation combined with inhibition of tumour cell
growth.
DISCUSSION
Angiogenesis is associated with intense endothelial cell cytokine-
dependent proliferation and hypoxia/re-oxygenation. Endothelial
cells produce ROS in response to cytokines (Matsubara and Ziff,
1986) and to hypoxia/re-oxygenation (Ratych et al, 1987; Inauen
et al, 1990; Lum et al, 1992; Zweier et al, 1988, 1994a,b; Terada,
1996). ROS have been implicated in the mechanism of damage
following ischaemia and during low-ﬂow hypoxia (McCord,
1985). Accumulated evidence has shown that vascular endothelial
cells are the most vulnerable targets for free radicals produced at
the time of organ reperfusion after cold preservation (Connor et
al, 1992) and that preservation of endothelial function is associated
with a reduction in superoxide radical generation (Mann et al,
1997).
SOD-1 is a protective enzyme responsible for maintaining lower
levels of superoxide radicals within the cell (Fridovich, 1978; Bann-
ister et al, 1987; Crapo et al, 1992). Previous studies have shown
that down-regulation of SOD-1 activity induces apoptosis of
neuronal cells (Troy and Shelanski, 1994) and that up-regulation
of SOD-1 by shear stress is an important mechanism preserving
the integrity of the endothelium after pro-apoptotic stimulation
(Dimmeler et al, 1999). In addition, we have recently shown that
transgenic mice over-expressing human SOD-1 demonstrate an
increased angiogenic potential compared to control parental non-
transgenic mice (Marikovsky et al, 2002). Alterations in the activity
of SOD-1 may therefore affect angiogenesis and angiogenesis-
dependent pathologies.
The data presented in this study identify TR as an effective inhi-
bitor of angiogenesis. Oral administration of TR, which was shown
here to inhibit SOD-1, almost completely abrogated the formation
of new blood vessels. The ability of TR to inhibit at low concentra-
tions the growth of cultured capillary endothelial cells and to
speciﬁcally induce apoptosis in endothelial cells unlike other cell
types examined, suggests that the drug acts directly on capillary
endothelial cells. Interestingly, this sensitivity was found predomi-
nantly in proliferating endothelial cells. Systemically administered
TR speciﬁcally abrogated the formation of new blood vessels, while
no evidence for damage in other tissues or in existing blood vessels
was observed.
Only a few specialized cell types, notably activated neutrophils
and activated endothelial cells, are currently known to produce
large quantities of ROS (Ryan and Vann, 1988). Increase in intra-
cellular ROS as well as exposure to extra-cellular source of ROS
(Shaikh et al, 1997; Suzuki et al, 1997) induce apoptosis in
endothelial cells. One potential source of ROS is xanthine oxidase
(XO) which was shown to generate free radicals in endothelial cells
(Zweier et al, 1994a). XO was found to be much higher in capillary
endothelial cells (Jarasch et al, 1986). Moreover, hypoxia was
shown to injure endothelial cells by increasing xanthine oxidase
activity (Terada et al, 1992). Another mechanism generating ROS
that could preferentially affect endothelial cells has recently been
identiﬁed (Beckman et al, 1990). It shows that superoxide and
nitric oxide can react rapidly to form peroxynitrite, a potent
ROS. Since endothelial cells produce both superoxide and nitric
oxide, they may be particularly vulnerable to oxidant injury by this
mechanism.
TR is a potent chelator of heavy metals. Chelation of enzymes’
metal moiety may lead to loss of activity. Copper is essential for
the enzymatic activity of SOD-1. We have shown that TR strongly
inhibits SOD-1 activity and that exogenously added copper and not
Zn
2+,N i
2+,F e
2+ or Mn
2+, was able to out-compete the inhibitory
effect of TR on endothelial cell growth. Inhibition of SOD-1 by TR
could decrease the capacity of endothelial cells to scavenge the
increased level of superoxides, resulting in growth arrest, apoptosis,
and inhibition of angiogenesis. These data are in good agreement
with recent ﬁndings demonstrating that another SOD-1 inhibitor
(Huang et al, 2000) – 2-methoxyoestradiol is also anti-angiogenic
(Fotsis et al, 1994). No damage was observed in already established
(non-proliferating) blood vessels in the treated animals. This obser-
vation is in accordance with our observation that TR does not
affect quiescent non-proliferating endothelial cells.
TR was previously shown to inhibit also other enzymes
such as aldehyde dehydrogenase, aldehyde oxidase and rat
lipoprotein lipase activity in adipose tissue (Freundt and Netz,
1977; Sanny and Weiner, 1987; Sadurska and Boguszewski,
1993). None of these enzymes is copper dependent. Our data
is consistent with previous ﬁndings demonstrating copper ions
are involved in the sequence of events leading to angiogenesis
(Raju et al, 1982; McAuslan et al, 1983), that cornea colo-
nised by capillaries induced by an angiogenic factor become
rich in copper ions (Ziche et al, 1982; Gullino, 1986), and
that depletion of copper by diet or by penicillamine inhibited
brain tumour angiogenesis and growth (Brem et al, 1990a,b;
Yoshida et al, 1993, 1995). It cannot be excluded that chela-
tion of copper by TR may exert an anti-angiogenic effect in
addition to SOD-1 inhibition.
We showed that antioxidants such as NAC and Tiron have
signiﬁcantly reversed the TR-mediated inhibition of cell growth,
indicating an involvement of oxidative stress in this process. In
addition, transfected PC12 cells over-expressing SOD-1, were more
resistant to cell growth inhibition by TR than the parental non-
transfected cells. This result further indicates that SOD-1 is
involved in the inhibitory effect of TR on endothelial cell growth.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 779–787Previous results, which demonstrated reduction of spontaneous
occurrence of tumours by TR, are consistent with our ﬁndings.
TR was shown to reduce the incidence of spontaneous leukaemia,
mammary ﬁbroadenoma and skin masses and to slightly reduce
pituitary and thyroid tumours in rats (Takahashi et al, 1983; Hase-
gawa et al, 1988; Maita et al, 1991). This reduction could be partly
attributed to its anti-angiogenic activity. TR was shown to be non-
clastogenic and non-carcinogenic in rats (Hasegawa et al, 1988)
and in the skin in male Swiss albino mice (George and Kuttan,
1995).
Angiogenesis is a tightly controlled process. Nevertheless, many
pathologies are driven by persistent unregulated neovascularisation.
Since C6 glioma tumour development as well as lung metastasis are
angiogenesis-dependent (Plate et al, 1992; Abramovitch et al, 1995;
Ikeda et al, 1995; Niida et al, 1995), it is conceivable that tumour
development in both models is affected by TR. Indeed, TR signiﬁ-
cantly reduced both Lewis lung metastatic growth and C6 tumor
development in vivo. The use of an orthotopic model would be
more clinically relevant and may involve different mechanisms of
angiogenesis. The inhibiting effect of TR in both tumour models
was achieved when administered systemically p.o. at low concentra-
tions, similar to those that effectively inhibited angiogenesis in vivo.
TR was inhibitory in vitro, for endothelial and for C6 glioma cells
as well as for Lewis lung carcinoma cells. It is possible thus, that
TR inhibition of tumour development and metastasis is mediated
through a combined effect on both angiogenesis and tumour cell
growth.
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